In the 1990s, the first disease-modifying therapies (DMTs) for multiple sclerosis (MS) were
injectable immunomodulatory (IM) drugs, including four different interferon-β preparations …

Objective: To assess the pooled risk of cancer in patients with multiple sclerosis. Methods:
We searched PubMed, Scopus, EMBASE, Web of Science, Ovid, google scholar and gray …

Background The association between multiple sclerosis (MS) and cancer has long been
investigated with conflicting results. Several reports suggest an increased cancer risk among …

Background Most studies that have investigated the association between multiple sclerosis
(MS) and cancer have suggested a reduced overall cancer risk and no effect of long-term …

Background Studies of cancer prevalence have produced conflicting results concerning the
relative risk of overall and specific sub-types of cancer in patients with multiple sclerosis …

Background: Epidemiological data reveal that 45% of persons with multiple sclerosis
(PwMS) in France are more than 50 years. This population more than 50 is more susceptible …

Background Long-term population-based safety studies are needed to investigate cancer
outcomes in people with multiple sclerosis (MS) treated with modern disease-modifying …

The inception of an organization solely dedicated to the investigation and ultimate cure of
multiple sclerosis (MS) was set in motion in 1946, when Silvia Lowry established the …

Multiple sclerosis (MS) may run a rapidly progressive monophasic course (the Marburg, or
malignant form), that carries a poor prognosis [1]. Autologous hematopoietic stem cell …

Background: il rischio di cancro nei pazienti con sclerosi multipla (SM) è un argomento di
crescente interesse. Sono disponibili pochi dati sul ruolo delle ultime terapie e sull'impatto …